Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2. J of Skin [Internet]. 2022 Nov. 16 [cited 2026 Apr. 17];6(6):s63. Available from: https://skin.dermsquared.com/skin/article/view/1818